

Letter to the Editor

Hemoglobinopathy and COVID-19

Dear Editor,


We would like to share ideas on the publication "Hemoglobinopathy and pediatrics in the time of COVID-19."¹ Vilela et al. concluded that, "Despite pediatric population with SCD needs more intensive care, the outcome after infection by COVID-19 is favorable."¹ A previous report from Iran noted that patients with thalassemia/hemoglobinopathy had a possible susceptible nature to severe COVID-19.² However, a report from Southeast Asia showed an opposite conclusion.³ Based on the data from our setting, Indochina, where beta-thalassemia and hemoglobin E are very common, only a few cases (less than 5) among more than 20,000 local COVID-19 patients had associated hemoglobinopathy. This marked low incidence might confirm the hypothesis on COVID-19 resistance of patients with hemoglobinopathy. Additionally, all infected cases with underlying hemoglobinopathy usually have mild symptoms. The effect of standard iron chelation therapy in patients with hemoglobinopathy is a possible explanation for mild COVID-19.⁴ Pharmacologically, the iron chelating agent can suppress endothelial inflammation, which is the main pathophysiologic mechanism in COVID-19.⁴

Conflicts of interest

None.

REFERENCES

1. Vilela TS, Braga JAP, Loggetto SR. Hemoglobinopathy and pediatrics in the time of COVID-19. *Hematol Transfus Cell Ther.* 2021;43(1):87–100.
2. Karimi M, Haghpanah S, Azarkeivan A, Matin S, Safaei A, De Sanctis V. Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: a nationwide Iranian experience. *Mediterr J Hematol Infect Dis.* 2021 Jan 1;13(1): e2021008.
3. Papadopoulos KI, Sutheesophon W, Manipalviratn S, Aw TC. A Southeast Asian perspective on the COVID-19 pandemic: hemoglobin E (HbE)-trait confers resistance against COVID-19. *Med Sci Monit Basic Res.* 2021 Jan 5;27: e929207.
4. Dalamaga M, Karampela I, Mantzoros CS. Commentary: could iron chelators prove to be useful as an adjunct to COVID-19 treatment regimens? *Metabolism.* 2020 Jul;108:154260.

Rujittika Mungmunpantipantip ^{a,*}, Viroj Wiwanitkit^b

^a Private Academic Consultant, Bangkok, Thailand

^b Dr DY Patil University, Pune, India

*Corresponding author at: Private Academic Consultant, Bangkok, Thailand

E-mail address: rujittika@gmail.com

(R. Mungmunpantipantip).

Received 19 March 2021

Accepted 14 April 2021

Available online 18 May 2021

<https://doi.org/10.1016/j.htct.2021.04.003>
2531-1379/

© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).